A Phase 1 interventional study of ABBV-8736 and ABBV-8736 in Healthy Volunteer, sponsored by AbbVie. Completed at 2 sites in United States. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-20.
Sponsored by AbbVie · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to assess the pharmacokinetics (PK), bioavailability, immunogenicity, safety, and tolerability of ABBV-8736 following subcutaneous (SC) administration relative to intravenous (IV) administration.
AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.
Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive IV ABBV-8736 on Day 1.
Drug: ABBV-8736
Participants will receive SC ABBV-8736 on Day 1.
Drug: ABBV-8736
Number of Participants with Adverse Events (AEs)
An AE is defined as any untoward medical occurrence in a patient or clinical investigation in which a participant is administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.
Time frame: Up to At Least 3 Months
Maximum Observed Serum Concentration (Cmax) of ABBV-8736
Cmax of ABBV-8736.
Time frame: Up to At Least 3 Months
Time to Maximum Observed Serum Concentration (Tmax) of ABBV-8736
Tmax of ABBV-8736.
Time frame: Up to At Least 3 Months
Area Under the Plasma Concentration-Time Curve (AUC) From Time 0 to the Time Last (AUClast) of ABBV-8736
AUClast of ABBV-8736.
Time frame: Up to At Least 3 Months
AUC From Time 0 to the Time Infinity (AUCinf) of ABBV-8736
AUCinf of ABBV-8736.
Time frame: Up to At Least 3 Months
Terminal Phase Elimination Rate Constant (β) of ABBV-8736
β of ABBV-8736.
Time frame: Up to At Least 3 Months
Terminal Elimination Half-Life (t1/2) of ABBV-8736
t1/2 of ABBV-8736.
Time frame: Up to At Least 3 Months
Apparent Clearance of the Analyte in Serum (CL) of ABBV-8736
CL of ABBV-8736.
Time frame: Up to At Least 3 Months
Plan to share: No
No publications or documents are linked to this record.
Ran from Feb 2026 to primary completion in Jun 2026, 4 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: ABBV-8736